Lumykras यूरोपीय संघ - आइसलैंडी - EMA (European Medicines Agency)

lumykras

amgen europe bv - sotorasib - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Omnic Hart hylki með breyttan losunarhraða 0,4 mg आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

omnic hart hylki með breyttan losunarhraða 0,4 mg

astellas pharma a/s* - tamsulosinum hýdróklóríð - hart hylki með breyttan losunarhraða - 0,4 mg

Medikinet CR (Medikinet retard) Hart hylki með breyttan losunarhraða 30 mg आइसलैंड - आइसलैंडी - LYFJASTOFNUN (Icelandic Medicines Agency)

medikinet cr (medikinet retard) hart hylki með breyttan losunarhraða 30 mg

medice arzneimittel pütter gmbh & co. kg* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 30 mg